Author(s): A. Zouhair, M. Ozsahin, M. Schaffer, S. Albrecht, F. Camus, P. Jichlinski, R.-O. Mirimanoff, A. Bischof Delaloye, J.-Y. Meuwly and J.O. Prior
Page: [2492 - 2502] Pages: 11
* (Excluding Mailing and Handling)
Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Keywords: Prostate cancer, bladder cancer, testicular cancer, positron emission tomography, F-18-fluorodeoxyglucose
Download PDF Flyer